With Alzheimer’s disease therapies finally reaching the market and hundreds of active clinical trials for therapies and diagnostics, it seems like every week brings another potential avenue to explore ...
The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...
In the last five years, neuronal pentraxins have emerged as potential markers of synaptic loss. In the case of NPTX2, researchers may now be able to explain why. In the March 29 Science Translational ...
Long COVID was identified in blood proteins, an analysis of longitudinal data suggested. Blood samples from long COVID patients showed changes to blood serum proteins at 6 months that indicated ...
In a recent study posted to the bioRxiv* preprint server, researchers investigated the expression of complement regulatory proteins (CRPs) in coronavirus disease 2019 (COVID-19) to identify potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results